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New York, New York
As the survival of patients with primary coronary events continues to increase, the number of
patients presenting with coronary artery disease unsuitable to further revascularization
techniques and symptoms refractory to medical therapy also continues to rise. The aims of
this review were to define the population of patients with refractory angina pectoris and to
present the therapeutic options currently available for this condition. Refractory angina
pectoris is defined, and traditional medical therapies are discussed. Then, current therapeutic
options for patients with refractory angina are extensively reviewed. A multitude of
therapeutic options exist for patients with refractory angina pectoris. Small, uncontrolled
studies have shown a potential benefit for additional antiplatelet and antithrombotic therapy.
In randomized trials, neurostimulation has been shown to be effective in reducing angina
symptoms. Enhanced external counterpulsation is a viable treatment option for select patients
with refractory angina. In many randomized trials, laser revascularization has been shown to
diminish angina symptoms, although no placebo-controlled studies exist to date. Gene
therapy is a promising area of research in this field. Percutaneous in situ coronary venous
arterialization is in its infancy, but may be able to treat many patients if proved successful. No
data support the role of chelation therapy in this population. Heart transplantation remains
a final option for these patients. Further research of the techniques mentioned in this review
is warranted. The importance of randomized, double-blinded, placebo-controlled trials
cannot be overemphasized, as the placebo effect of these therapies is probably
marked. (J Am Coll Cardiol 2002;39:923–34) © 2002 by the American College of
Cardiology Foundation
Angina pectoris, the symptom that most often brings
patients with ischemic heart disease to medical attention,
represents an imbalance between myocardial oxygen supply
and demand. This condition is most commonly due to
atherosclerotic disease of the coronary arteries, resulting in a
critical narrowing of the vessels. Conventional approaches
to restoring this balance between oxygen supply and de-
mand focus on disruption of the underlying disease process
through medications, life-style modifications or revascular-
ization techniques, such as coronary artery bypass graft
surgery (CABG) or percutaneous coronary interventions
(PCI), including balloon angioplasty, stents and atherec-
tomy techniques.
An increasing number of patients with coronary artery
disease (CAD), however, have ischemic symptoms that are
unresponsive to both conventional medical therapy and
revascularization techniques. This is because life expectancy
is increasing, even for very sick patients, many of whom
have already undergone multiple PCIs or previous surgical
revascularization, and thus are not candidates for additional
procedures. Such patients are said to have refractory angina
pectoris, and an understanding of the therapeutic options
for these patients is becoming more vital for physicians
treating patients with CAD today. It has been estimated
that 100,000 patients each year may be diagnosed as
having this condition (1).
DEFINING PATIENTS WITH REFRACTORY ANGINA
Two criteria must be met before a patient is labeled to have
refractory angina pectoris: objective ischemia must produce
severe symptoms, and all known conventional therapies
must be exhausted. Patients with refractory angina have
either marked limitation of ordinary physical activity or are
unable to perform any ordinary physical activity without
discomfort (Canadian Cardiovascular Society [CCS] func-
tional class III or IV). There must be some objective
evidence of ischemia, as demonstrated by exercise treadmill
testing, stress imaging studies or coronary physiologic stud-
ies.
Symptoms must continue despite maximally tolerated
medical therapy and with a consensus that revascularization
by either PCI or CABG is not feasible. It should be noted
that many patients are not able to benefit from traditional
medical therapy due to side effects of the medications. All
attempts at “maximizing” medical and life-style treatments,
including the use of drug combinations, avoidance of nitrate
tolerance, initiation of an exercise program and discontin-
uation of tobacco, must be made. Secondary causes of
angina, such as anemia and uncontrolled hypertension,
should be excluded.
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Furthermore, a consensus regarding the inappropriate-
ness of revascularization procedures should be established.
Coronary artery disease that is not amenable to PCI or
CABG may be deemed amenable for revascularization
when different interventional cardiologists or cardiac sur-
geons are asked for their evaluation. Hence, a second and
sometimes third opinion regarding the potential for revas-
cularization should always be sought before labeling a
patient as having refractory angina pectoris.
TRADITIONAL THERAPIES
The majority of patients with mild to moderate angina
(CCS class I/II) can be treated adequately with anti-anginal
medications. Medications commonly used for the treatment
of angina pectoris are listed in Table 1.
Beta-blockers remain the first-line drug for the treatment
of angina pectoris. Beta-blockers decrease myocardial oxy-
gen demand by decreasing heart rate and contractility
during stress. A slower heart rate also increases the diastolic
filling time available for coronary perfusion (which occurs
mostly in diastole). This is important for patients with fixed
coronary stenoses in whom the ratio of systolic to diastolic
perfusion is abnormally high. Beta-blockers thereby increase
exercise tolerance and reduce the frequency of anginal
attacks.
Calcium channel blockers act as pure arterial (including
coronary) vasodilators, with variable effects on cardiac con-
duction and contractility. Phenylalkylamines, such as vera-
pamil, and benzothiazepenes, such as diltiazem, have neg-
ative inotropic and chronotropic effects. Thus, verapamil
and diltiazem retard the increase in myocardial oxygen
demand at submaximal work loads, resulting in an increase
in the anginal threshold. Dihydropyridines, such as nifedi-
pine, produce negligible decreases in myocardial oxygen
demand; instead, they increase myocardial oxygen supply by
increasing coronary blood flow through changes in vascular
tone. They should not be used as the sole medical therapy.
Nitrates are endothelial-independent vasodilators. They
dilate vascular smooth muscles even in vessels without
endothelium. At therapeutic doses, nitrates exert their most
prominent vasodilatory effects on systemic veins and con-
ductance arteries. This results in an increase in myocardial
oxygen supply and a decrease in myocardial oxygen demand.
Venodilation leads to decreased left ventricular volume and
thus diminished systolic wall stress and oxygen require-
ments. Furthermore, nitrates have been shown to cause
modest stenosis dilation and to relieve coronary vasocon-
striction related to endothelial dysfunction. Flow through
collateral channels feeding ischemic myocardial regions is
also increased. Clinically, exercise tolerance increases and
anginal attacks decrease.
Aspirin is recommended for all patients with known
CAD. It irreversibly acetylates platelet cyclooxygenase,
thereby limiting the production of proaggregatory throm-
boxane A2. Platelets have been implicated in the disruption
of atherosclerotic plaque, with subsequent thrombus forma-
tion, leading to the development of unstable angina or
myocardial infarction, or both. For patients allergic to
aspirin, clopidogrel or ticlopidine can be used as antiplatelet
therapy.
With the recent publication of the Heart Outcomes
Prevention Evaluation (HOPE) study (2), angiotensin-
converting enzyme (ACE) inhibitors have received renewed
interest as an anti-ischemic medication. This large, ran-
domized, placebo-controlled trial demonstrated a significant
22% decrease in mortality and recurrent ischemic events in
patients with known vascular disease or diabetes plus one
other cardiovascular risk factor and normal left ventricular
function who received the ACE inhibitor ramipril versus
placebo. Two similar multicenter studies—the Prevention
of Events with ACE inhibition (PEACE) and European
Trial on the Reduction of Cardiac Events with Perindopril
in Stable Coronary Artery Disease (EUROPA)—are also
evaluating the anti-ischemic effects of ACE inhibitors in
patients with CAD and normal left ventricular function.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
bFGF  basic fibroblast growth factor
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
EDTA  ethylenediamine-tetraacetic acid
EECP  enhanced external counterpulsation
EMM  electromechanical mapping
LAD  left anterior descending coronary artery
LDL  low-density lipoprotein
LMWH  low-molecular-weight heparin
PCI  percutaneous coronary intervention
PICAB  percutaneous in situ coronary venous
arterialization
PICVA  percutaneous in situ coronary venous
arterialization
PTMLR  percutaneous transmyocardial laser
revascularization
rFGF  recombinant fibroblast growth factor
SCS  spinal cord stimulation
SPECT  single-photon emission computed
tomography
TENS  transcutaneous electrical nerve stimulation
TMLR  transmyocardial laser revascularization
VEGF  vascular-endothelial growth factor
Table 1. Medical Therapy Commonly Prescribed for
Angina Pectoris
1. Beta-blockers—decrease heart rate and contractility
2. Calcium channel blockers—act as arterial vasodilator and decrease
heart rate and contractility.
3. Nitrates—act as venous and arterial vasodilator
4. Antiplatelet agents—for anti-inflammatory activity
5. Angiotensin-converting enzyme inhibitors—improve endothelial
function, and for anti-inflammatory activity
6. Statins—improve endothelial function, and for anti-inflammatory
activity
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The role of ACE inhibitors in patients with mild anginal
symptoms is unknown.
In multiple trials, lipid-lowering agents have been shown
to decrease recurrent coronary events in patients with
known CAD and even to prevent CAD episodes in patients
without known CAD (3). Besides reducing low-density
lipoprotein (LDL) cholesterol, hepatic hydroxymethyl glu-
taryl coenzyme A reductase inhibitors (statins) possess
anti-inflammatory and plaque-stabilizing properties (4).
Recently, the Atorvastatin Versus Revascularization Treat-
ment (AVERT) trial, using high-dose atorvastatin in pa-
tients with mild to moderate anginal symptoms, showed a
reduction in recurrent coronary events, as compared with
patients treated with conventional lipid-lowering therapy
and elective angioplasty (5). It is not known what level of
LDL cholesterol reduction is optimal in refractory angina,
nor has any study been performed on the efficacy of lipid
lowering in patients with such chronic symptoms.
For the majority of patients in whom medical therapy is
unable to control ischemic symptoms, revascularization
techniques are widely available in the U.S. In 1999, over
700,000 PCIs were performed, and the number of patients
able to receive percutaneous interventions should only
increase as technology and operator experience advance (6).
For those patients requiring surgical revascularization, the
introduction of less invasive techniques will also increase the
already large numbers (over 400,000 in the U.S.) of CABG
procedures performed worldwide (6).
Still, a large group of patients are inadequately managed
with these traditional therapies. These patients cannot
tolerate additional medications and have an anatomy un-
suitable for initial or further mechanical revascularization.
Furthermore, because the underlying process of atheroscle-
rosis is not completely halted by these traditional therapies,
new lesions can and usually do develop. These patients with
refractory angina pectoris continue to have severe symptoms
limiting their quality of life. The therapeutic options avail-
able for these generally desperate patients are outlined in
Table 2.
ALTERNATIVE MEDICAL THERAPY
Additional antiplatelet agents. Although aspirin use is
widespread among patients treated with CAD, platelet
inhibition is only attenuated, and coronary events continue
to occur. Clopidogrel is a thienopyridine derivative that
blocks adenosine diphosphate–mediated platelet aggrega-
tion. Combination therapy with aspirin and clopidogrel has
already been studied, with promising results in cerebrovas-
cular diseases (7).
Despite results from the Clopidogrel in Unstable angina
to prevent Recurrent Events (CURE) trial, which demon-
strated a 20% relative reduction in cardiac events in patients
presenting with an acute coronary syndrome when given the
combination of aspirin and clopidogrel, caution must be
used in extending these results to patients with refractory
angina (8). It is speculative whether this benefit would be
demonstrated in patients with more stable refractory angina.
Low-molecular-weight heparins. The recent develop-
ment of low-molecular-weight heparins (LMWH) allows
for the outpatient use of this pharmacologic therapy. In
addition, thrombin generation is ameliorated by the in-
creased ratio of anti–factor Xa to anti–factor II activity seen
in LMWH, as compared with unfractionated heparin (9).
This has led to speculation that these agents may be useful
in patients with refractory angina.
There have been two randomized trials evaluating the
efficacy of LMWH in the outpatient management of
patients with stable angina pectoris. Melandri et al. (10)
conducted a double-blinded, randomized, placebo-
controlled trial in 29 patients with stable, effort-induced
angina and angiographically proven CAD. This study com-
pared conventional anti-anginal treatment with the study
medication, which added the LMWH parnaparin over
three months. The patients who received parnaparin
showed a statistically significant decrease in fibrinogen levels
and an improvement in the time to both 1-mm ST-segment
depression and peak ST-segment depression. There was no
increase in major bleeding events in the LMWH group.
In a second study, Quyyami et al. (11) studied 23 patients
with stable CAD in a randomized, placebo-controlled
fashion, comparing conventional anti-anginal therapy with
similar therapy plus subcutaneous dalteparin sodium for
four weeks. Compared with placebo, patients who received
dalteparin had significantly less frequent anginal episodes,
an increase in exercise tolerance and an increase in the
rate–pressure product during the time to ischemia. Finally,
a smaller percentage of patients had a decrease in left
ventricular function with exercise. There was no increase in
major bleeding episodes. There was a marked placebo effect
in this trial, however.
It remains to be seen whether LMWH should be
recommended in patients with refractory angina pectoris.
Concerns about its safety profile have not been appropriately
addressed, to date. A larger randomized, placebo-
controlled, double-blinded study will be needed before this
therapy can unequivocally be deemed efficacious and safe.
Thrombolytic agents. Although thrombolytic therapy has
been proven to reduce morbidity and mortality in the setting
of acute ST-segment elevation myocardial infarction, it has
not been proven to be beneficial in patients who present
Table 2. Therapeutic Options for Refractory Angina Pectoris
1. Pharmacologic therapy—additional antiplatelet agents, thrombolytic
therapy, low-moledcular-weight heparins, partial fatty acid oxidation
inhibitors
2. Neurostimulation
3. Enhanced extracorporeal counterpulsation
4. Laser revascularization (surgical and percutaneous)
5. Gene therapy
6. Percutaneous in situ coronary venous arterialization
7. Chelation therapy
8. Heart transplantation
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with unstable angina or non–ST-segment elevation myo-
cardial infarction (12). Given its ability to improve blood
viscosity, however, it has been postulated that intermittent
low-dose thrombolytic therapy may lead to enhanced cor-
onary blood flow at both the microcirculatory and macro-
circulatory levels in patients with refractory angina pectoris.
Two trials showing the potential benefits of this therapy
have been conducted. First Schoebel et al. (13) performed a
pilot study using bolus intravenous urokinase in 20 patients
with refractory angina pectoris. Each patient had elevated
baseline fibrinogen levels. After 12 weeks of therapy, fibrin-
ogen levels declined by 34%. The number of anginal events
per week decreased by 74% in the urokinase group, as
compared with baseline. There was a 51% increase in
exercise tolerance and time to 1-mm ST-segment depres-
sion. However, no placebo group was compared with the
urokinase arm, and thus the placebo effect of this therapy
cannot be fully determined.
Leschke et al. (14) conducted a randomized, dose-
response trial comparing weekly high-dose versus low-dose
urokinase. Ninety-eight patients were followed for 12
weeks. Only the high-dose group had significant changes
from baseline when measuring pre- and post-fibrinogen
levels, plasma viscosity and red cell aggregation. Patients in
the high-dose urokinase group reported significantly de-
creased anginal events. Furthermore, only the high-dose
group noted increased exercise capacity and time to 1-mm
ST-segment depression. Bleeding complications were sim-
ilar in both groups. A major limitation of this study was the
absence of a placebo control group.
Currently, intermittent administration of thrombolytic
therapy for the treatment of refractory angina pectoris
appears safe. Fibrinogen levels are reduced, leading to
decreased red blood cell aggregation and plasma viscosity.
Clinically, exercise capacity is increased and subjective
anginal episodes are also decreased. However, because of the
small number of patients studied and the lack of a placebo
control group, the value of thrombolytic therapy in patients
with refractory angina is uncertain.
Partial fatty acid oxidation inhibitors. Ranolazine repre-
sents a new class of compounds called partial fatty acid
oxidation inhibitors, which has the potential to be the first
new anti-anginal drug class in the U.S. in more than 20
years. Ranolazine increases efficient cardiac utilization of
oxygen during stress by maximizing glucose utilization of
oxygen versus fatty acid oxidation, which is far more
inefficient. In the recently completed Combination Assess-
ment of Ranolazine In Stable Angina (CARISA) trial, 823
patients already taking background beta-blocker or calcium
channel blocker therapy were randomized to either ranola-
zine (high or low dose) or placebo (15). Patients in both
ranolazine groups demonstrated a significant increase in
exercise duration after two weeks of therapy, which was
maintained after 12 weeks. Furthermore, the high-dose
ranolazine group demonstrated a decreased frequency in
anginal events per week, as compared with the placebo
group. Long-term studies with this new class of drugs are
planned.
NEUROSTIMULATION
Various methods have been described for the palliation of
angina by interruption or modification of the afferent neural
signals through which pain is perceived. Different surgical
techniques have been used to interrupt the innervation of
the heart, including autotransplantation, sympathectomy
and plexectomy. More recent studies using transcutaneous
electrical nerve stimulation (TENS) and spinal cord stimu-
lation (SCS) have produced the most promising results.
Mannheimer et al. (16) first described the beneficial
effects of TENS in the early 1980s. Based on the “gate-
control theory,” high-frequency stimulation of large non-
nociceptive myelinated type A fibers inhibits the impulse
through smaller, unmyelinated type C fibers, thereby reduc-
ing the activation of central pain receptors. In addition,
there is a reduction in sympathetic discharge, leading to a
decrease in cardiac work load and myocardial oxygen de-
mand.
In TENS, two electrodes are applied to the chest—one in
the dermatome with the highest intensity of projected pain
and the other in the contralateral dermatome. The stimulus
intensity is adjusted to just below the individual’s pain
threshold. Early studies demonstrated an increase of exer-
cise capacity with a concurrent reduction of ischemia noted
on the exercise electrocardiogram (ECG) (17). There was a
decrease in the anginal symptoms reported, and nitrate use
was noticeably decreased. Side effects included skin irrita-
tion as a result of the high-frequency direct current and
limited physical activity during treatment. Because of the
paresthesias associated with effective treatment, no random-
ized, placebo-controlled trial is possible, considering the
difficulty in producing similar paresthesias in a placebo
group.
Spinal cord stimulation appears to be the most promising
neurostimulatory technique for refractory angina. In SCS,
the epidural space is punctured at the level of the fourth or
sixth thoracic vertebra, and an electrode is introduced to the
level of the first or second thoracic vertebra. An electrode
stimulator is then placed subcutaneously in the upper left
abdomen. By a mechanism similar to TENS, stimulation of
these electrodes leads to decreased pain sensation and
sympathetic outflow, as well as redistribution of myocardial
blood flow to ischemic areas (18). Mannheimer et al. (19)
noted a reduction in anginal symptoms, an increase in
exercise capacity and a reduction in the degree of ST-
segment depression at a given work load in patients receiv-
ing SCS versus control subjects. In another study, Hautvast
et al. (20) demonstrated decreased ischemic ECG changes
on ambulatory 48-h monitoring in a group of patients with
refractory angina pectoris.
Two larger studies evaluating SCS have shown more
convincing evidence. The Electrical Stimulation versus Cor-
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onary Bypass Surgery (ESBY) trial was a randomized,
prospective study comparing SCS with CABG in 104
patients with known CAD who were considered at high risk
for CABG or who would have no proven benefit from
CABG (21). After six-month follow-up, CABG and SCS
appeared to be equivalent in terms of symptom relief, with
significant decreases in angina reported by both groups. The
CABG group had a significant increase in exercise capacity
and less ST-segment depression, as compared with the SCS
group. However, 7 of the 51 patients in the CABG group
died during the follow-up period, whereas there was only
one death in the SCS group.
Greco et al. (22) recently published a multicenter, retro-
spective study of patients treated with SCS. After 23
months, 103 of the 517 patients studied had died. Spinal
cord stimulation resulted in a significant decrease in New
York Heart Association functional class. This study con-
cluded that chronic SCS does not adversely affect mortality
in patients with refractory angina pectoris, but it does
improve symptoms. On a cautionary note, no placebo group
was included.
In summary, neurostimulation is an emerging therapeutic
option for patients with refractory angina pectoris. Symp-
toms appear to improve with either TENS or SCS, al-
though the data for SCS are more convincing. There is
objective evidence that both modalities may improve isch-
emia. Concerns include the invasive nature of SCS and the
cutaneous side effects of TENS. Furthermore, a strong
placebo component may be present. Currently, interest in
neurostimulation is centered mainly in Europe.
ENHANCED EXTERNAL COUNTERPULSATION
Enhanced external counterpulsation (EECP) uses timed,
sequential inflation of pressure cuffs located around the legs
to increase venous return, decrease left ventricular afterload
and increase diastolic filling pressure. The end result is an
increase in coronary perfusion pressure and, theoretically,
less angina. Using a mechanism similar to the intra-aortic
balloon pump (i.e., counterpulsation), the cuffs in EECP
inflate, as shown on the ECG during diastole, sequentially
from the calves to the upper thighs, resulting in augmented
diastolic aortic pressure. Venous return is also increased
during cuff inflation. The cuffs then deflate at the beginning
of systole, thereby reducing diastolic aortic pressures and
lowering myocardial afterload.
The exact mechanism by which EECP may improve
anginal symptoms is controversial. Besides the effects of
diastolic augmentation and increased coronary perfusion
pressure, as described previously, animal models have sug-
gested an increase in the collateral circulation with counter-
pulsation. Basic science reports have suggested that an
increase in sheer stress in the coronary circulation activates
multiple pathways, leading to possible angiogenesis or
opening of previously dormant vessels or both (23).
In 1999, Arora et al. (24) published the results of the
MUlticenter STudy of Enhanced External Counter Pulsa-
tion (MUST-EECP) trial, the first randomized, placebo-
controlled, multicenter trial evaluating the efficacy of EECP
in patients with refractory angina. This trial enrolled 139
outpatients with end-stage CAD and persistent symptoms.
The patients were randomized to either the active EECP
group (300 mm Hg cuff inflation) or the inactive sham
EECP group (75 mm Hg cuff inflation). All patients
received a total of 35 one-hour sessions over four to seven
weeks. Pre- and post-measurements on average exercise
duration, time to 1-mm ST-segment depression, daily
average number of anginal attacks and nitroglycerin use
were recorded. Figure 1 outlines the study protocol and
results.
After treatment, the EECP group showed a significant
increase in the time to 1-mm ST-segment depression and a
decrease in anginal episodes. There was a trend toward
decreased nitroglycerin use in the active EECP group.
Exercise duration increased in both groups, but the inter-
group difference was not significant. Adverse effects in-
cluded abrasions on the skin, lower leg and back. It should
be noted that many patients were excluded from this study,
including those with a recent myocardial infarction, recent
CABG, recent cardiac catheterization, unstable angina,
overt congestive heart failure or left ventricular ejection
fraction 30%, significant valvular disease, significant pul-
monary vascular disease, severe hypertension, arrhythmias
interfering with ECG triggering and bleeding diathesis.
A more recent study by Urano et al. (25) supports the
findings seen in the MUST-EECP trial. Twelve patients
with stable angina pectoris, similar to those enrolled in the
MUST-EECP trial, were given a total of 35 h of treatment
with EECP. Compared with baseline, post-EECP exercise
variables were all significantly improved, including exercise
duration, time to 1-mm ST-segment depression and rate–
pressure product at peak exercise. Reversible perfusion
defects on thallium imaging decreased from 35% to 21%.
Furthermore, hemodynamic measurements also signifi-
cantly improved (diastolic filling, left ventricular end-
diastolic pressure, left ventricular peak filling rate, end-
diastolic volume per second and time to peak filling rate). A
decrease in plasma brain natriuretic peptide levels after
EECP treatment was noted.
Most recently, the International EECP Patient Registry
showed an improvement of at least one angina class in 81%
of the patients (n 978) with CCS class III or IV refractory
angina pectoris (26). Only 1.1% of the patients withdrew
from the study, and quality-of-life measurements after
EECP were significantly improved. The major limitation of
this study is the lack of a control group.
At this time, EECP is not applicable for all patients with
refractory angina pectoris. Many patients are ineligible for
therapy, including those with severe pulmonary vascular
disease and congestive heart failure. The sessions are time-
consuming, awkward and uncomfortable. Although the
exact mechanism by which angina may improve is still
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undefined, EECP represents a viable treatment option for
certain patients with severe, uncontrollable ischemia.
LASER REVASCULARIZATION
Laser revascularization creates channels through heart mus-
cle for the purpose of directly revascularizing ischemic
myocardium. Techniques to accomplish this task have been
advanced over the last century. Reptilian heart physiology
provided the basis of modern laser revascularization. Rep-
tiles do not have significant epicardial coronary circulation.
Instead, 90% of the heart’s blood supply is delivered directly
to heart muscle from the ventricle through a network of
channels.
The development of laser revascularization dates back to
1933, when Wearn et al. (27) hypothesized the importance
of epicardial conductance vessels and extracardiac and ven-
triculocoronary anastamoses (sinusoidal network) in myo-
cardial perfusion. In 1954, Vineberg (28) reported successful
tunneling of the left internal mammary artery into the
myocardium (the Vineberg procedure), but this approach
was not pursued because CABG began soon after. In 1986,
Okada et al. (29) were the first to successfully create laser
channels in the human myocardium.
In modern transmyocardial laser revascularization
(TMLR), a left lateral thoracotomy is performed and 10 to
50 transmural channels are created using a high-energy
carbon dioxide laser, which is triggered electrocardiograph-
ically. Intraoperative transesophageal echocardiography can
confirm the presence of successful transmyocardial puncture
by the appearance of bubbles or microcavities within the
myocardium or left ventricular cavity. The epicardial chan-
nel opening usually closes spontaneously or after brief
manual compression, and the entire procedure can be
performed within 2 to 3 h. There is no need for cardiopul-
monary bypass or cardioplegia.
Horvath et al. (30) published the results of TMLR as the
sole therapy in patients with refractory angina in a nonran-
domized, multicenter study. They reported significant im-
provements in anginal symptoms and myocardial perfusion
on thallium imaging in 75% of these patients over
12-month follow-up. This study provided the impetus for
four future randomized, prospective, controlled surgical
trials assessing the safety and efficacy of TMLR in patients
with refractory angina pectoris.
The first trial comparing TMLR in addition to conven-
tional medical management versus medical management
alone was conducted by Schofield et al. (31) in Europe. A
total of 188 patients with CCS class III or IV (69% class III)
angina were randomly assigned to either group. After 12
months of follow-up, there was no statistically significant
difference in exercise capacity or 12-min walking distance.
Although anginal class scores significantly decreased in the
TMLR group, and there was a significantly decreased need
for anti-anginal medications and few hospital admissions in
the laser group, these were secondary end points. The
perioperative mortality rate in the TMLR group was 5%.
Overall survival at 12 months was not significantly different.
The investigators concluded that no objective evidence from
TMLR could be seen from this trial, and that TMLR could
not be advocated as an effective alternative for patients with
refractory angina.
In a second study, Frazier et al. (32) randomized 192
patients with mostly CCS class IV angina (69%) to receive
either TMLR or continued medical therapy. After 12
months of follow-up, the TMLR group had a significant
improvement in anginal class, quality-of-life scores and
Figure 1. Trial design and results of MUST-EECP. Source: Arora et al.
(24), with permission. CAD coronary artery disease; CCSCCanadian
Cardiovascular Society class; ETT  exercise treadmill test.
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single-photon emission computed tomographic (SPECT)
thallium imaging. Finally, only 2% of the patients treated
with TMLR were hospitalized with unstable angina over
the following 12 months, as compared with a 69% hospi-
talization rate seen in the medically managed group. There
was no difference in overall survival. The perioperative
mortality rate associated with TMLR was 3%. Of note,
there was a 59% crossover rate from the medical therapy
group to the TMLR group over the duration of the study.
Frazier et al. (32) concluded that TMLR improved cardiac
perfusion and clinical status over a 12-month period in
patients with predominantly refractory CCS class IV an-
gina.
Allen et al. (33) published a third, similar study compar-
ing TMLR plus medical therapy versus medical therapy
alone in patients with refractory angina pectoris. This trial
enrolled 275 patients, all with CCS class IV refractory
angina. After one year, the TMLR group had a significant
improvement in anginal class scores, a higher rate of cardiac
event-free survival, a decrease in cardiac-related hospital
admissions and a higher rate of freedom from treatment
failure. Quality-of-life scores and exercise tolerance were
also statistically significantly improved. Interestingly, there
were no differences in myocardial perfusion between the two
groups, as assessed by thallium imaging. There was no
significant difference in overall survival. Of note, 32% of the
patients originally assigned to the medical therapy only arm
crossed over into the TMLR arm over the course of the study.
Most recently, Burkhoff et al. (34) published the results of
the Angina Treatments-Lasers And Normal Therapies In
Comparison (ATLANTIC) study comparing TMLR plus
medical therapy to medical therapy alone. A total of 182
patients with mostly (62%) CCS class IV refractory angina
were followed for 12 months. The TMLR group demon-
strated a significant increase in exercise tolerance, an im-
provement in anginal class scores and superior quality-of-
life measurements. However, there was no difference in
myocardial perfusion or ejection fraction between the
groups, as measured by echocardiography and dipyridamole
thallium scanning. There was no statistically significant
difference in overall mortality.
In an editorial on TMLR, Lange and Hillis (35) re-
mained cautious about the results of the TMLR trials. They
emphasized the desperate nature of these patients with
refractory angina and noted the lack of objective evidence of
improvement (e.g., mortality benefit, ejection fraction, myo-
cardial perfusion) in the TMLR trials. Furthermore, they
noted the high crossover rates seen in Frazier and Allen’s
studies, the lack of a placebo arm and the wide variation in
improvements in anginal class scores from each different study.
PERCUTANEOUS
TRANSMYOCARDIAL LASER REVASCULARIZATION
Transmyocardial laser revascularization is now being per-
formed percutaneously, using a less invasive catheter-based
approach. Results with this so-called “percutaneous
transmyocardial laser revascularization (PTMLR),” while
preliminary, are similar to those reported in the surgical
TMLR data (36).
Oesterle et al. (37) recently published the results of the
Potential Angina Class Improvement From Intramyocardial
Channels (PACIFIC) trial, a multicenter, randomized
study comparing PTMLR in addition to medical therapy
versus medical therapy alone in 221 patients with both CCS
class III or IV refractory angina. At 12 months, exercise
tolerance significantly increased in the PTMLR group, as
did anginal class scores and quality-of-life measurements.
There was no significant difference in overall mortality.
There was no measurement of myocardial perfusion in this
trial.
A similar trial by Whitlow (38) compared PTMLR plus
medical therapy to medical therapy alone in 330 patients
with CCS class II, III or IV refractory angina. After 12
months, there was a significant improvement in anginal
class scores, exercise tolerance and quality-of-life measures.
There was no difference in one-year survival between the
groups.
The results of the DMR In Regeneration of Endomyo-
cardial Channels Trial (DIRECT), led by Leon (39),
however, have tempered the initial enthusiasm surrounding
myocardial laser therapy. This randomized, placebo-
controlled, prospective trial enrolled 298 patients into three
treatment arms: placebo PTMLR procedure, low-dose
PTMLR (10 to 15 channels created) or high-dose PTMLR
(20 to 25 channels created). The unique aspect of the trial
was that none of the patients enrolled knew which arm of
the study they were in. After six months of follow-up, the
trial was stopped prematurely after all three groups noted a
similar increase in exercise duration, exercise time to symp-
toms and exercise time to 1-mm ST-segment depression.
Furthermore, there was a similar increase in the percentage
of patients who reported at least a two-class improvement in
anginal symptoms after six months and in all indexes
reflecting quality of life. There were no differences in major
adverse cardiac events after six months of follow-up.
In summary, TMLR is the only Food and Drug
Administration-approved device used for the treatment of
refractory angina pectoris. The mechanism of improvement
in symptoms is unclear at present. It is debatable whether
laser channels remain patent for any significant amount of
time. Randomized clinical trials without a placebo control
group have produced consistent improvements in anginal
symptoms, exercise duration and quality-of-life perceptions.
Improvement in myocardial perfusion has not been vali-
dated by this technique. More research is needed before
TMLR and PTMLR can be considered scientifically sound,
rather than just producing an improvement by a large
placebo effect. Table 3 summarizes the trials performed to
date using TMLR/PTMLR.
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GENE THERAPY
Gene therapy has been proposed as a potential means of
treating multiple clinical conditions, such as post-PCI
restenosis, bypass graft restenosis and refractory angina
pectoris. Over the past decade, substantial progress has been
made in the field of cardiovascular gene therapy. Research in
animal models has already shown promising results on the
feasibility of gene transfer technology as a viable treatment
modality for severe CAD (40). Still, although proof of
principle has been established in these preclinical animal
models, the task of demonstrating convincing efficacy data
in humans has been meticulous and slow.
Fundamentally, angiogenesis should be distinguished
from arteriogenesis. The former is the process of formation
of new vessels that lack tunica media, whereas the latter
describes the phenomenon of new arteries appearing with
fully developed tunica media. An example of arteriogenesis
would be the formation of visible angiographic collateral
channels in patients with severe CAD or peripheral vascular
disease. An example of angiogenesis is the formation of
capillaries along the border zone of a myocardial infarction.
Isner et al. (41) reported the first evidence of clinical
efficacy of vascular angiogenesis in a patient in 1996.
Improvement in blood supply to an ischemic limb after
intra-arterial gene transfer of a plasmid encoding for vascu-
lar endothelial growth factor (VEGF) was documented.
Using an angioplasty balloon coated with plasmid in the
distal popliteal artery, the patient showed an increase in
collateral vessels at the knee, mid-tibia and ankle after four
weeks, as verified by angiography and Doppler flow studies.
However, after five months, the patient’s leg was removed
below the knee, as gangrene of the limb could not be
reversed.
After this seminal report, Baumgartner et al. (42) re-
ported a phase-1 trial employing plasmid-encoding VEGF
delivered intramuscularly in patients with critical limb
ischemia. Gene transfer was performed in 10 limbs of nine
patients with nonhealing ischemic foot ulcers. After intra-
muscular gene delivery, circulating levels of VEGF were
increased, and various clinical measurements, including the
ankle-brachial index and magnetic resonance angiography,
showed qualitative evidence of improved distal flow in eight
limbs. Ulcers improved or healed in four of seven patients,
and after 10 weeks, tissue samples in the injected regions
showed evidence of proliferating endothelial cells.
Losordo et al. (43) published the first randomized,
phase-1 clinical trial testing the safety of intramyocardial
delivery of VEGF plasmid in humans with myocardial
ischemia. Using a left anterior thoracotomy, the plasmid
VEGF deoxyribonucleic acid (DNA) was directly injected
into the myocardium at risk in five patients with symptom-
atic angina in whom conventional therapy had failed.
Dobutamine SPECT showed evidence of reduced ischemia
in all five patients after 30 and 60 days. Rentrop collateral
flow was increased in all five patients after 60 days. No
adverse events were reported in this small group of patients.
Although these preliminary, small-scale reports provided
initial promise with regard to the efficacy of vascular gene
therapy, questions on the use of plasmids have arisen.
Plasmids (small, circular DNA pieces) represent a relatively
inefficient means of delivering a gene protein. They are
taken up inefficiently by most cells and are unprotected
against cellular defense mechanisms. Hence, it has been
presumed that proteins expressed by plasmids would be
expressed only transiently. Still, the safety of these plasmids
has been confirmed by numerous animal studies and pre-
liminary human studies.
Recent studies have used an adenoviral vector for gene
transport. Although the adenoviral vector is able to achieve
a much higher titer of gene product in a cell line, the
potential for vector-induced cytotoxicity remains. Gene
expression using this system, however, is still transient, and
a subsequent dose is not recommended because of potential
immune responses.
Using the adenoviral vector, Rosengart et al. (44) re-
ported the delivery of VEGF to 21 patients by direct
myocardial injection into an area of reversible ischemia,
either as an adjunct to conventional CABG or as the sole
therapy through a mini-thoracotomy. After 30 days, all
patients reported a subjective decrease in their anginal
symptoms. Coronary angiography and stress sestamibi scan-
ning of wall motion showed improvement in the majority of
patients. In patients given only gene transfer with revascu-
larization, treadmill exercise assessment showed improve-
ment in half of the patients, although there was no improve-
ment in those patients who received CABG in addition to
Table 3. Randomized Trials of Laser Revascularization








Frazier et al. (32) 1999 192 12 CO2 72% vs. 13% (p  0.01) 85% vs. 79%
Allen et al. (33) 1999 275 12 H-YAG 76% vs. 32% (p  0.01) 84% vs. 89%
Burkhoff et al. (34) 1999 182 12 H-YAG 48% vs. 14% (p  0.01) 95% vs. 90%
Schofield et al. (31) 1999 188 12 CO2 24% vs. 4% (p  0.01) 89% vs. 96%
Oesterle et al. (37) (PTMLR) 2000 221 12 H-YAG 34% vs. 14% (p  0.01) 93% vs. 97%
Leon (39) (PTMLR) 2000 298 6 H-YAG 34% vs. 42% 98% vs. 97%
Whitlow et al. (PTMLR) 2001 330 12 H-YAG 32% vs. 10% (p  0.01) 92% vs. 93%
*No statistically significant difference in survival.
CO2  carbon dioxide; H-YAG  holmium yttrium-aluminum-garnet; PTMLR  percutaneous transmyocardial laser revascularization.
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gene transfer. There were no systemic or cardiac-related
adverse events.
In animal studies, basic fibroblast growth factor (bFGF)
has reportedly promoted angiogenesis, improved endothelial
vasodilatory function and improved myocardial perfusion.
Laham et al. (45) were the first to study the transfer of
bFGF in humans as a stimulus for angiogenesis in those
with severe CAD. This randomized, double-blinded,
placebo-controlled, phase-1 trial compared high- and low-
dose bFGF administration, delivered through sustained-
release microcapsules in ischemic, viable, but ungraftable
myocardium, versus placebo, in patients undergoing
CABG. After three months of follow-up on 24 patients,
stress nuclear imaging showed no improvement in the
placebo and low-dose group, although the high-dose group
showed significant improvement in the ischemic territory.
Magnetic resonance imaging also showed a strong trend
toward a reduction in the target ischemic area in the
high-dose group. There were two operative deaths reported,
in addition to three Q-wave myocardial infarctions periop-
eratively.
Udelson et al. (46) studied 59 patients with refractory
angina pectoris after administration of both intracoronary
(n  45) or intravenous (n  14) recombinant fibroblast
growth factor (rFGF). After 180 days, improvements in
both stress and rest myocardial perfusion abnormalities
using SPECT perfusion imaging were noted. This phase-1
trial, however, was not placebo-controlled and showed no
improvement in the left ventricular ejection fraction.
Vale et al. (47) used left ventricular electromechanical
mapping (EMM) as a means of assessing efficacy in 13
patients with chronic refractory angina who had been given
plasmid DNA encoding for VEGF directly into the myo-
cardium through a mini-thoracotomy. Electromechanical
mapping uses electromagnetic field sensors to integrate
real-time information from intracardiac electrograms ac-
quired at multiple endocardial locations. By detecting elec-
trical activity in areas of poor local shortening, viable
myocardium can be located. After 60 days, EEM showed a
decrease in the area of ischemic myocardium, which was
confirmed by SPECT perfusion imaging. All patients re-
ported a significant decrease in their anginal symptoms and
nitroglycerin use, and their exercise capacity had signifi-
cantly increased after 180 days. No control group, however,
was present, and no change in ejection fraction was noted.
Questions concerning a possible placebo effect in these
previous studies provided the impetus for the Adenovirus
GENe Therapy (AGENT) trial (48). This is the first
randomized, double-blinded, placebo-controlled trial of
gene therapy. This trial enrolled 79 patients with docu-
mented CAD by angiography, objective evidence of isch-
emia during a 3-min exercise treadmill test and baseline
CCS class II or III angina. Sixty patients received direct
injection of recombinant adenovirus 5 FGF-4 and 19
patients received placebo. Follow-up treadmill tests were
performed at 4 and 12 weeks, and the active treatment
group had a greater improvement in exercise duration and a
30% increase in exercise tolerance time, as compared with
the placebo group. It should be noted that the placebo group
showed marked improvement from baseline, demonstrating
the importance of double-blinded, placebo-controlled trials
in this population.
Currently, gene therapy represents an exciting avenue of
research in the treatment of ischemic vascular disease.
However, because there is a lack of randomized, placebo-
controlled trials, the true efficacy of gene therapy cannot be
definitively evaluated. It is still not known whether the
improvements in myocardial perfusion can be attributed to
angiogenesis. There remains a theoretic risk of worsening
the atherosclerotic process in native vessels. Hopefully, the
proper vector, yielding high efficiency without toxicity, will
be identified in future trials, in addition to the ideal mode of
delivery (intravenous vs. intracoronary; percutaneous vs.
surgical). Table 4 summarizes the current trials performed
in vascular gene therapy to date.
Table 4. Vascular Gene Therapy Trials
Study (Ref.) Agent Used No. of Patients/Target Results
Baumgartner et al. (42) Plasmid VEGF 9/limb ischemia Levels of VEGF increased, ABI and MRA improved and
4 of 7 ulcers improved.
Losordo et al. (43) Plasmid VEGF 5/intramyocardial Dobutamine SPECT and collateral flow improved in all
5 patients.
Rosengart et al. (44) Adenoviral VEGF 21/intramyocardial Wall motion improved in most patients, as assessed by
angiography and stress sestamibi scanning.
Laham et al. (45) bFGF through microcapsules 24/intramyocardial The high-dose group showed a significant improvement,
by stress nuclear imaging, after 3 months.
Udelson et al. (46) Recombinant FGF 59/IV and intracoronary There was improvement in both stress and rest SPECT
perfusion imaging after 180 days.
Vale et al. (47) Plasmid VEGF 13/intramyocardial Electromechanical mapping and SPECT imaging showed
a decrease in ischemia myocardium.
Grines et al. (48) Recombinant adenovirus FGF 79/intracoronary The treatment group showed a significant increase in
exercise duration and exercise tolerance time, as
compared with the placebo group.
ABI  ankle-brachial index; bFGF  basic fibroblast growth factor; IV  intravenous; MRA  magnetic resonance angiography; SPECT  single-photon emission computed
tomography; VEGF  vascular endothelial growth factor.
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PERCUTANEOUS IN SITU
CORONARY VENOUS ARTERIALIZATION
Percutaneous in situ coronary venous arterialization (PICVA)
is a percutaneous approach to CABG that redirects arterial
blood flow from the occluded, offending artery into an
adjacent coronary vein, thereby arterializing the vein and
providing retroperfusion to ischemic myocardium. Even in
the most severe cases of CAD, the venous system is
generally free of atherosclerosis, and the individual veins are
dispensable, owing to a redundant venous system. Anec-
dotal reports documenting relief from angina using coronary
retroperfusion from the 1940s to the 1970s inspired the
modern-day revival of this technique (49).
Oesterle et al. (50) reported the first successful case of
PICVA in a 53-year-old diabetic German man diagnosed
with CCS class IV angina refractory to medical therapy and
not a good candidate for CABG or PCI. The patient had a
chronic total occlusion of his mid-left anterior descending
coronary artery (LAD), with diffuse, distal LAD disease.
Figure 2 outlines the technical aspects of this procedure.
The procedure requires that the occluded artery and corre-
sponding great vein be imaged. A needle is advanced
proximal to the occlusion in the artery and into the adjacent
vein under ultrasound guidance. A connector is then placed
in between the structures, and a plug is placed proximal to
the coronary sinus so that venous retroperfusion may occur.
This patient has been free of anginal symptoms for over
one year, and the follow-up angiogram at three months
showed complete patency of the arterialized anterior inter-
ventricular vein. A three-month stress sestamibi scan
showed increased perfusion in the previously ischemic area,
and stress testing showed no exercise-induced chest pain at
previously ischemic levels.
Percutaneous in situ coronary artery bypass (PICAB) is
also an advancing technology for this group of patients with
refractory angina in whom arterial blood flow is redirected
from a diseased artery to an adjacent coronary vein, and then
rerouted back to the artery after the lesion (51). Thus, the
coronary vein acts as an in situ coronary bypass conduit
rather than as a means of retroperfusion. This technology
requires that two arteriovenous fistulae be created—one on
either side of the artery blockage—and that the vein be
blocked both distally and proximally.
Although the potential for PICVA and PICAB, as
treatment for patients with poor anatomy for traditional
revascularization procedures, is enormous, currently these
technologies must be considered experimental. A larger
clinical trial proving its safety and feasibility must be
completed before these newer forms of revascularization can
become a practical option for patients with refractory
angina.
CHELATION THERAPY
Chelation therapy is the least scientifically grounded option
for patients with refractory angina pectoris. It was first
proposed as a potential treatment for atherosclerosis in the
1950s, after it was noted that patients treated for lead
poisoning felt relief of their anginal symptoms after under-
going ethylenediamine-tetraacetic acid (EDTA) therapy.
Since then, various small, uncontrolled studies have been
published, with conflicting results.
The hypothesis for atherosclerosis regression involves the
ability of EDTA to extract calcium from the atherosclerotic
plaque. This hypothesis has never been scientifically vali-
dated and, in fact, is no longer applicable to the present
understanding of the atherosclerotic process. Still, as the
debate over the efficacy of chelation therapy continues,
numerous alternative medicine clinics have sprung up in
Europe and the U.S., promoting its efficacy.
Ernst (52) systematically reviewed the evidence from
randomized, placebo-controlled, double-blinded trials eval-
uating chelation therapy (intravenous EDTA with vitamin
Figure 2. Percutaneous in situ coronary venous arterialization. Source: Oesterle et al. (50), with permission.
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and trace mineral supplementation) for the treatment of
peripheral arterial occlusive disease. After reviewing four
studies involving over 220 patients, he concluded that
chelation therapy was not superior to placebo. There was no
significant improvement in walking distance, nor any dif-
ference in objective measures, such as angiographic regres-
sion or ankle-arm index in both the short- and long-term
studies. Furthermore, Ernst advocated that chelation ther-
apy be considered “obsolete,” considering the potential for
serious side effects, including potentially lethal hypocalce-
mia and severe kidney dysfunction.
Most recently, the Program to assess Alternative Treat-
ment strategies to achieve Cardiac Health (PATCH) trial
released its results, showing the ineffectiveness of chelation
therapy (53). Eighty-four patients with stable angina were
randomized to receive either EDTA treatment or placebo.
After six months, there was no difference in exercise
tolerance, as both groups showed similar improvement.
There were no deaths or heart attacks and no difference in
hospital re-admission rates. This trial also demonstrated the
power of a placebo effect in certain populations.
Currently, there is no convincing evidence that chelation
therapy has any benefits. It has potentially lethal side effects
and should not be considered a viable alternative therapeutic
option for patients with refractory angina pectoris. The
American Heart Association has published an official rec-
ommendation concerning chelation therapy in patients with
CAD after a review of the published data, and it concluded
that there was no scientific evidence to demonstrate any
benefit from this form of therapy (54). The American
College of Cardiology, Food and Drug Administration and
National Institutes of Health have all concurred with this
statement.
HEART TRANSPLANTATION
For patients who have disabling angina and in whom all
conventional and alternative treatment modalities have
failed, heart transplantation should be considered. Heart
transplants are severely limited in number, with only
3,000 transplantations being performed worldwide. One-
year survival is 80%, with an average 10-year survival rate
of 40% (55). This must be discussed with each patient, as
some patients may be expected to live longer with their
current symptoms, as compared with their survival expect-
ancy after receiving a transplant.
CONCLUSIONS
End-stage angina pectoris refractory to conventional med-
ical therapy and not amenable to either CABG or PCI
represents a truly desperate and frustrating condition for
both the patient and physician. This ever-growing popula-
tion of patients requires a thorough re-evaluation of con-
ventional therapeutic options. These patients must be
placed on the maximal tolerable doses of current anti-
anginal medications. Furthermore, it is imperative to con-
firm that the patient’s coronary anatomy is truly not ame-
nable to revascularization. A number of interventional
cardiologists and cardiac surgeons may need to assess the
patient before he or she is labeled as having “refractory
angina pectoris.”
For those patients with no other options, new emerging
therapies for refractory angina provide hope. Additional
antiplatelet/antithrombotic therapy may improve anginal
symptoms and improve exercise capacity. Innovative revas-
cularization techniques, such as PICVA and PICAB, are
currently being investigated. Neurostimulation and EECP
may benefit select groups of patients. Angiogenic gene
therapy is a promising field that has yet to show convincing
efficacy in humans. Laser revascularization is currently the
most thoroughly studied modality and has been shown to
significantly decrease anginal symptoms in most studies.
However, given the lack of placebo-controlled groups in the
majority of all studies in this population, the placebo effect
cannot be ruled out as an important component of improve-
ment for all of the options just mentioned. Heart transplan-
tation is available as a final option. Ultimately, both the
physician and patient must determine which alternative
treatment may work best for them.
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